B. Riley Forecasts Immunic’s FY2024 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at B. Riley reduced their FY2024 EPS estimates for Immunic in a research note issued on Tuesday, November 26th. B. Riley analyst W. Wood now forecasts that the company will earn ($0.97) per share for the year, down from their prior forecast of ($0.93). B. Riley has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($0.80) EPS.

Several other equities analysts have also recently issued reports on IMUX. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright assumed coverage on shares of Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Leerink Partners reiterated an “outperform” rating and set a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.80.

Immunic Stock Up 3.3 %

Shares of IMUX opened at $1.24 on Thursday. The company has a market cap of $111.70 million, a P/E ratio of -1.01 and a beta of 1.88. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The firm’s 50 day moving average price is $1.34 and its 200 day moving average price is $1.34.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Immunic in the first quarter valued at about $25,000. Jane Street Group LLC increased its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares in the last quarter. State Street Corp lifted its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.00% of the stock is owned by insiders.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.